Jan 7, 2022
On this episode, Cole and I are joined by Trevor Walker, PharmD Candidate 2022. We begin by comparing and contrasting the original SSRIs as well as new agents like vortioxetine and vilazodone. We then review some serotonin (5-HT) receptors and how their activity (or inhibition) determine and mitigate outcomes and adverse effects. We close by reviewing the ANTLER trial that was published in NEJM in September 2021.
If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. You can find our account at the website below:
If you have any questions for Cole or me, reach out to us on any of the following:
Text - 415-943-6116
Mike - mcorvino@corconsultrx.com
Cole - cswanson@corconsultrx.com
Instagram and other social media platforms - @corconsultrx
This podcast reviews current evidence-based medicine and pharmacy treatment options. This podcast is intended to be used for educational purposes only and is intended for healthcare professionals and students. This podcast is not for patients and not intended as advice or treatment.